Owing to the hyperphagia, all three groups significantly gained BM, initially from increased gut fill and subsequently from gains in both FM and FFM.
As previously reported (Winer et al, 2009a, b), reconstitution of CD4+ T cells (PBS group) significantly reduced body weight gain (Fig 6C), glucose tolerance, insulin sensitivity and serum insulin levels (Fig 6D).
While the intervention group significantly lost fat mass, the control group gained fat mass, from baseline to follow up (Table 3).
Among the chili-fed groups, chili meal group significantly showed higher average daily gain (ADG) and lower feed conversion ratio (FCR) than the chili granule group (P=0.014 and P=0.027) but they were not significantly different from those of chili powder group.
Participants in the intervention group gained significantly less weight than those in the control group.
The lifestyle intervention resulted in a lower proportion of women exceeding the recommendations of the Institute of Medicine (IOM) for GWG (38%% vs. 60%%, p < 0.05), and participants in the intervention group gained significantly less weight than those in the control group (14.1 vs. 15.6 kg, p < 0.05).
HPC group gained significantly greater weight than HPMA, HPRA and all three LP groups (P = 0.024), while no difference was observed between HPMA and HPRA groups regarding weight gain.
Patients in the pioglitazone alone group gained significantly more body weight than those in the pioglitazone plus dapagliflozin groups.
Specifically, the HPC group gained significantly greater weight than the HPMA, the HPRA and all LP groups.
Results The New MOW group gained significantly more weight between baseline and 3 months than did the Traditional MOW group (2.78 lb vs −1.46 lb, respectively, P =.0120) and again between baseline and 6 months (4.30 lb vs −1.72 lb, respectively, P =.0004).
